Clinical Trial Update: Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring trained immunity via dual-pathway inhibition in patients with coronary artery disease; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Snippet

Sponsor: Radboud University Medical Center | Conditions: Coronary Artery Disease | Phase 4 | Status: UNKNOWN